Search Results
Nov 25, 2025, 04:44 ET 메나리니 그룹, 제67회 미국혈액학회 연례 학술대회에서 ELZONRIS®(tagraxofusp-erzs) 관련 신규 데이터 발표
617. 급성 골수성 백혈병: 상업적으로 이용 가능한 치료법: 포스터 III 포스터 발표
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 19:37 ET NOWRX INC. INVESTOR NOTICE: Squitieri Fearon LLP and Moore Law PLLC Announce that NowRx, Inc. Investors Have Opportunity to Lead Securities Class Action Lawsuit
failed to disclose: (i) material, adverse facts concerning NowRx's financial condition (ii) that NowRx was on the brink of bankruptcy or insolvency; (iii) that NowRx had hired an investment bank to explore a sale or raise significant funds so that it could continue operations; (iv) that as of December
More news about: Moore Law PLLC
Nov 24, 2025, 17:56 ET Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III studiesOne-time dose of Itvisma replaces SMN1 gene, potentially reducing the need for chronic SMA treatmentGene replacement
More news about: Novartis
Nov 24, 2025, 17:31 ET Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight
in April 2025, the company is finalising the Phase III confirmatory trial design for SBS patients dependent on parenteral support. The company plans to seek FDA alignment in Q4 2025. If alignment is achieved, Ironwood expects to start the Phase III trial in the first half of 2026.Zealand Pharma's
More news about: DelveInsight Business Research, LLP
Nov 24, 2025, 16:52 ET Menarini Group gibt neue Daten zu ELZONRIS® (Tagraxofusp-erzs) bekannt, die auf der 67. Jahrestagung und Ausstellung der American Society of Hematology vorgestellt werden
617. Akute myeloische Leukämien: Kommerziell verfügbare Therapien: Poster IIIPoster-Präsentation
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 16:44 ET Menarini Group annonce de nouvelles données sur ELZONRIS® (tagraxofusp-erzs) qui seront présentées lors de la 67e réunion annuelle de l'American Society of Hematology
617. Leucémies myéloïdes aiguës : Thérapies disponibles dans le commerce: Affiche IIIPrésentation d'un poster
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 12:00 ET Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
642. Chronic LymphocyticLeukemia: Clinical and Epidemiological:Poster IIIMonday, Dec. 8
More news about: Eli Lilly and Company
Nov 24, 2025, 10:27 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster IIIPoster presentation
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:20 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster IIIPoster presentation
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:00 ET Leica Brings M EV1 Digital Camera with EVF to the M World - M EV1 Camera Now In Stock at B&H
incredible all-around performer. Other returning features include Leica Content Credentials and 64GB of internal memory, all powered by the Maestro III image processor.Because of its lack of optical viewfinder, the
More news about: B&H Photo
Nov 24, 2025, 09:00 ET Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules
safety data and topline results for the phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, and
More news about: Azitra, Inc.
Nov 24, 2025, 08:45 ET Skye Bioscience, Inc. Class Action: The Gross Law Firm Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.DEADLINE: January 16, 2026 Shareholders
More news about: The Gross Law Firm
Nov 24, 2025, 08:45 ET The Gross Law Firm Reminds Firefly Aerospace Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FLY
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: The Gross Law Firm
Nov 24, 2025, 08:45 ET Investors in DexCom, Inc. Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: The Gross Law Firm
Nov 24, 2025, 08:30 ET BitMine Immersion (BMNR) Announces ETH Holdings Reach 3.63 Million Tokens, and Total Crypto and Cash Holdings of $11.2 Billion
BitMine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support BitMine's goal of acquiring 5% of ETH
More news about: BitMine Immersion Technologies, Inc.
Nov 24, 2025, 08:00 ET Isaac Hayes III, Ty Walker, and Keisha Perry Walker Partner to Bring Microdramas to Fanbase
Isaac Hayes III, to produce and distribute original microdramas launching in Q1 2026.
More news about: Fanbase Social Media Inc.
Nov 24, 2025, 08:00 ET U.S. Securities and Exchange Commission Establishes Stoner Cats Fair Fund
MAIL MUST BE POSTMARKED BY MAY 23, 2026. THE CLAIM FORM MUST BE ACCOMPANIED BY APPROPRIATE SUPPORTING DOCUMENTS FOR EACH TRANSACTION LISTED IN PARTS II–III OF THE CLAIM FORM.Claim DeterminationsThe Fund Administrator will send a Claim Status Notice within
More news about: Epiq
Nov 24, 2025, 07:43 ET Metavesco Unveils Transformational OTCfi ACCESS Platform and Strategic Roadmap During High-Impact Livestream Event
its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; and (iii) growth strategy and operating strategy. The words "may", "would", "will", "expect", "estimate", "can", "believe", "potential", and similar expressions
More news about: Metavesco, Inc.
Nov 24, 2025, 07:30 ET ELSE ANNOUNCES INVESTMENT FOR GROSS PROCEEDS OF UP TO US$1,280,000
"Company") announces that the Company has entered into a new convertible security funding agreement (the "Agreement") with Lind Global Fund III LP, an entity managed by The Lind Partners, LLC, a New York-based institutional fund manager (together, "Lind"). Under the terms of the Agreement,
More news about: Else Nutrition Holdings Inc.
Nov 24, 2025, 07:20 ET Perrigo Company plc (PRGO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP
to make substantial capital and operational expenditures above Perrigo's outwardly stated cost estimates to remediate the infant formula business; (iii) there were significant manufacturing deficiencies in the facility for Perrigo's infant formula business; and (iv) as a result of the foregoing, Perrigo's
More news about: Robbins Geller Rudman & Dowd LLP
Nov 24, 2025, 07:01 ET Einride, a Leader in Electric and Autonomous Freight, Appoints Anubhav Verma as Chief Financial Officer Ahead of Planned Public Listing
the first half of 2026 subject to customary closing conditions, including regulatory approvals.About Legato Merger Corp. III:Legato Merger Corp. III (NYSEAMERICAN: LEGT) is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition
More news about: Einride
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 24, 2025, 06:55 ET Einride, a Leader in Electric and Autonomous Freight, Appoints Anubhav Verma as Chief Financial Officer Ahead of Planned Public Listing
the first half of 2026 subject to customary closing conditions, including regulatory approvals.About Legato Merger Corp. III:Legato Merger Corp. III (NYSEAMERICAN: LEGT) is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition
More news about: Einride
Nov 24, 2025, 06:32 ET Apollo Hospitals rolls out its third facility in Maharashtra with a 400-bed quaternary care facility in Pune
digital PET-CT and LINAC radiotherapy, the hospital will offer precise and compassionate treatment. Supported by over 100 critical care beds, level III neonatal and pediatric ICUs, and exclusive mother and child floors, the facility will offer diverse patient accommodations alongside premium amenities.
More news about: Apollo Hospitals
Nov 24, 2025, 06:00 ET Hyperscale Data Joins the Global Top 100 Public Bitcoin Treasury Companies with Current Holdings of Approximately 382 Bitcoin
Long-Term Commitment "We are proud to join the top 100 public Bitcoin treasuries companies globally," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "Our strategy hasn't changed; we mine Bitcoin daily and we buy Bitcoin weekly. Our
More news about: Hyperscale Data Inc.